| Document |
Document Title |
|
WO/2023/237124A1 |
Disclosed are a crocin suspension and use thereof in the preparation of a rapid-acting antidepressant drug. The crocin suspension comprises an active ingredient and an auxiliary material in the following mass ratio: crocin:suspending age...
|
|
WO/2023/236263A1 |
The present invention provides a benzoxazole derivative, a preparation method therefor, and an application thereof. The benzoxazole derivative provided by the present invention has a structure as represented by formula (I). Experimental ...
|
|
WO/2023/235864A1 |
Disclosed herein are methods and kits for assessing a. risk of subject developing autism spectrum disorder (ASD). The methods can include determining a level of Limosilactobacillus reuteri in a sample from the subject, or receiving resul...
|
|
WO/2023/233357A1 |
The disclosure relates to a subcutaneous dosage of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-containing NMDA r...
|
|
WO/2023/232997A1 |
The invention relates to a synergistic multi-ionic complex providing potentiated preventive and therapeutic responses to inflammation by modulating the pathways of immunity. It is a composition comprising mineral salts, including at leas...
|
|
WO/2023/232462A1 |
The present application provides a synthetic nutritional composition comprising milk fat globule membrane (MFGM) in the range of about 10 μg/100 kcal to about 1500 mg/100 kcal for use in improving neurological development in a paediatri...
|
|
WO/2023/233185A1 |
The present invention relates to the field of medicaments. Particularly, the present invention refers to the combination of cannabidiol (CBD) and alpha-lipoic acid at a specific dosage regimen and related application with "entourage effe...
|
|
WO/2023/231402A1 |
Provided is use of UbV.E4B protein in the preparation of a medicament for promoting central nervous regeneration. The UbV.E4B protein promotes the axonal regeneration of a central nervous system by selectively inhibiting a Ube4b ubiquiti...
|
|
WO/2023/233277A1 |
The present invention relates to lyophilized pharmaceutical compositions of copper histidinate and one or more pharmaceutically acceptable excipients. It also relates to processes for preparing such compositions.
|
|
WO/2023/232083A1 |
The present invention belongs to the field of biomedicine, and relates to a beta 2-microglobulin blocking peptide, and a pharmaceutical composition and the use thereof. In particular, the present invention relates to an isolated polypept...
|
|
WO/2023/235360A1 |
This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders,...
|
|
WO/2023/235166A1 |
The present invention relates to crystalline fine particle forms of 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl
)propyl)thieno[2,3-b]pyridine-5-carboxamide potassium salt (PRX-3140) for particle delivery systems (PDS) wi...
|
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/235734A1 |
The present disclosure provides deuterated compounds and their use as sodium channel blockers in the treatment or prevention of various diseases or disorders associated with sodium channels.
|
|
WO/2023/235502A1 |
This disclosure relates to novel pharmaceutical compositions comprising cyclohex-2- enylidene / 3, 3 -dimethylindoline compounds; a method of treating or ameliorating a cardiovascular disease or disorder, asthma, or narcolepsy in a subje...
|
|
WO/2023/232882A1 |
A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid comprises phospholipids, for use in improving the cognitive development in an infant born to a mother with hyperglycemia during pregnancy.
|
|
WO/2023/235500A1 |
A method of reducing the risk of a cocaine‐addicted subject relapsing in addiction is provided, the method including administering to the subject a combination of an effective amount of humanized 2E2 (h2E2) monoclonal antibody and an e...
|
|
WO/2023/233183A1 |
The present invention relates to the field of medicaments. Particularly, the present invention refers to the combination of cannabidiol (CBD) and resveratrol at a specific dosage regimen and related application with "entourage effect-lik...
|
|
WO/2023/233164A1 |
Compounds of formula (I) wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrom...
|
|
WO/2023/233437A1 |
The present invention relates to some RNA sequences which have been found effective in the treatment of a neurological disorder. Specifically, the neurological disorder is an autism spectrum disorder or autism and/or epilepsy.
|
|
WO/2023/235726A2 |
Guide RNAs and CRISPR/Cas systems targeting a C9orf72 gene, lipid nanoparticles or viral vectors comprising such CRISPR/Cas systems, and cells or animals comprising such CRISPR/Cas systems are provided. Methods of repressing transcriptio...
|
|
WO/2023/233665A1 |
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...
|
|
WO/2023/230718A1 |
The present invention provides a method of determining the amount of a psilocybin in a sample, the method comprising contacting a cell which expresses ABCF1 with the sample, comparing the expression of ABCF1 with a standard to determine ...
|
|
WO/2023/235648A1 |
Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.
|
|
WO/2023/235319A1 |
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...
|
|
WO/2023/235433A1 |
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula (I). Also disclosed are methods of...
|
|
WO/2023/234330A1 |
The present invention addresses the problem of providing an EGFR CAR-T cell which is expected to be effective against a tumor in which an EGFR is expressed. The present invention provides: a polynucleotide encoding a chimeric antigen rec...
|
|
WO/2023/234620A1 |
The present invention relates to a novel strain having resistance to methylglyoxal and activity to reduce advanced glycation end products (AGEs), and a composition including the strain. The strain and the composition not only have resist...
|
|
WO/2023/233329A1 |
The present disclosure relates to methods of treating cocaine addiction by administrating 5-methoxy-2-aminoindan, or a salt thereof, to a subject in need thereof in a therapeutically effective amount. The disclosure also relates to metho...
|
|
WO/2023/230649A1 |
The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/232966A1 |
Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
|
|
WO/2023/232764A1 |
The invention provides methods of treatment of a neurodegenerative disease in a subject, which methods comprise orally administering to said subject a methylthioninium (MT) containing compound, wherein said administration is at a dosage ...
|
|
WO/2023/233051A1 |
The invention relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition sensitive to risperidone or to paliperidone with risperidone in a patient who receives one or more inhib...
|
|
WO/2023/231948A1 |
Disclosed are a class of ISR inhibitors, a method for preparing same, and use thereof. The present invention belongs to the technical field of biopharmaceutics. The compound of the present invention is a compound having a structure of fo...
|
|
WO/2023/235880A1 |
The disclosure provides compounds of Formula (I) and salts thereof for use in medical treatment.
|
|
WO/2023/235725A2 |
Nuclease agents, including guide RNAs and CRISPR/Cas systems, targeting a C9orf72 gene, lipid nanoparticles or viral vectors comprising such nuclease agents, and cells or animals comprising such nuclease agents are provided. Methods of m...
|
|
WO/2023/235548A1 |
Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as...
|
|
WO/2023/235541A1 |
In an aspect, the disclosure relates to a liquid pharmaceutical composition comprising, consisting essentially of, or consisting of gemfibrozil and an aqueous solvent. The disclosure also relates to methods of making the liquid pharmaceu...
|
|
WO/2023/231778A1 |
Provided are a transgenic expression cassette capable of treatment of mucopolysaccharidosis type IIIA, an application thereof, an optimized nucleic acid molecule encoding N-sulfoglucosamine sulfohydrolase (SGSH), a designed and optimized...
|
|
WO/2023/234166A1 |
This antiepileptic composition contains one of or both of a bacterium of the genus Bifidobacterium and a culture thereof. The bacterium of the genus Bifidobacterium may be Bifidobacterium breve. The bacterium of the genus Bifidobacterium...
|
|
WO/2023/235790A1 |
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a ...
|
|
WO/2023/233395A1 |
The present invention provides extracellular vesicles (EVs) loaded with conjugates of an active agent and a hydrophilic compound such as a carbohydrate, methods for preparation and loading of said EVs, composition comprising the EVs and ...
|
|
WO/2023/232171A1 |
Title of the invention: Heterocyclic compounds for the prevention and therapy of circadian rhythm disorders The present invention provides heterocyclic compounds of general formula I (I) and their pharmaceutically acceptable salts, where...
|
|
WO/2023/234675A1 |
The present invention relates to antisense oligomers against monoamine oxidase B and a use thereof, and to: antisense oligomers that regulate the amount of genes, specifically, mRNA or protein, that code for monoamine oxidase B; and a us...
|
|
WO/2023/234312A1 |
Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited t...
|
|
WO/2023/231346A1 |
Disclosed is use of N1-dihydrocaffeoyl-N10-caffeoyl spermidine in preparing a drug, a health care product or functional food. The present invention belongs to the technical field of drug chemistry. In a dosage range of 2-100 mg/kg given ...
|
|
WO/2023/207574A9 |
Provided is a fusion protein, comprising: a transferrin-binding protein, and arylsulfatase A (ARSA) or a functional active fragment thereof. The transferrin-binding protein comprises a polypeptide, an antibody or an antigen-binding fragm...
|
|
WO/2023/235785A1 |
The present disclosure relates to methods for the treatment of depressive disorders (e.g., major depressive disorder) with 1,2,4-triazolone derivatives. In some embodiments, the methods include selecting a human subject for treatment of ...
|
|
WO/2023/234759A1 |
The present invention relates to a sulfanone derivative or a pharmaceutically acceptable salt thereof, and a composition containing the derivative as an active ingredient for the prevention or treatment of cancer, and the sulfanone deriv...
|
